# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 13, "Diabetes Care", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasJournal> \"Diabetes Care\"."
1, PublicationYear, 16, 20, "2013", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasPublicationYear> \"2013\"."
9, Title, 101, 285, "Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasTitle> \"Adding once - daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin : a 24 - week , randomized , placebo - controlled comparison ( GetGoal - L ) .\"."
2, Frequency, 108, 120, "once - daily", "", 
79568, Lixisenatide, 121, 133, "lixisenatide", "", 
4, Type2Diabetes, 138, 153, "type 2 diabetes", "", 
28, Precondition, 138, 206, "type 2 diabetes inadequately controlled by established basal insulin", "", "<http://ctro/data#Population_45452> <http://ctro/data#hasPrecondition> \"type 2 diabetes inadequately controlled by established basal insulin\"."
121, Insulin, 199, 206, "insulin", "", 
6, Duration, 211, 220, "24 - week", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasCTduration> \"24 - week\"."
7, Randomized, 223, 233, "randomized", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
8, Placebo, 236, 243, "placebo", "", 
10, Author, 286, 295, "Riddle MC", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Riddle MC\"."
11, Author, 304, 313, "Aronson R", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Aronson R\"."
12, Author, 316, 322, "Home P", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Home P\"."
13, Author, 325, 332, "Marre M", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Marre M\"."
14, Author, 335, 347, "Niemoeller E", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Niemoeller E\"."
15, Author, 350, 359, "Miossec P", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Miossec P\"."
16, Author, 362, 368, "Ping L", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Ping L\"."
17, Author, 371, 375, "Ye J", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasAuthor> \"Ye J\"."
18, Author, 378, 390, "Rosenstock J", "", 
19, USA, 477, 480, "USA", "", "<http://ctro/data#Population_45452> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
143, ObjectiveDescription, 516, 731, "To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasObjectiveDescription> \"To examine the efficacy and safety of adding the once - daily glucagon - like peptide - 1 receptor agonist ( GLP - 1RA ) lixisenatide to established basal insulin therapy alone or together with metformin , in people\"."
20, Frequency, 565, 577, "once - daily", "", "<http://ctro/data#Intervention_45478> <http://ctro/data#hasFrequency> \"once - daily\"."
79569, Lixisenatide, 637, 649, "lixisenatide", "", 
138, Insulin, 671, 678, "insulin", "", 
23, Metformin, 710, 719, "metformin", "", 
27, Precondition, 725, 795, "people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )", "", "<http://ctro/data#Population_45452> <http://ctro/data#hasPrecondition> \"people with type 2 diabetes and elevated glycated hemoglobin ( HbA1c )\"."
144, ObjectiveDescription, 732, 797, "with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasObjectiveDescription> \"with type 2 diabetes and elevated glycated hemoglobin ( HbA1c ) .\"."
24, Type2Diabetes, 737, 752, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
25, HbA1c, 766, 785, "glycated hemoglobin", "", 
26, HbA1c, 788, 793, "HbA1c", "", 
31, DoubleBlind, 843, 857, "double - blind", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
32, Parallel, 860, 876, "parallel - group", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
33, Placebo, 879, 886, "placebo", "", 
34, NumberPatientsCT, 923, 926, "495", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasNumberPatientsCT> \"495\"."
149, Insulin, 952, 959, "insulin", "", 
150, Precondition, 972, 999, "inadequate glycemic control", "", 
36, Randomized, 1005, 1015, "randomized", "", 
79571, Lixisenatide, 1023, 1035, "lixisenatide", "", "<http://ctro/data#Medication_45496> <http://ctro/data#hasDrug> <http://ctro/data#Lixisenatide>."
38, DoseValue, 1036, 1038, "20", "", "<http://ctro/data#Medication_45496> <http://ctro/data#hasDoseValue> \"20\"."
39, Microgram, 1039, 1042, "Î¼ g", "", "<http://ctro/data#Medication_45496> <http://ctro/data#hasDoseUnit> <http://ctro/data#Microgram>."
40, Placebo, 1046, 1053, "placebo", "", "<http://ctro/data#Medication_45503> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
41, Duration, 1058, 1066, "24 weeks", "", 
157, Insulin, 1075, 1082, "insulin", "", 
43, Hypoglycemia, 1120, 1132, "hypoglycemia", "", 
44, HbA1c, 1135, 1140, "HbA1c", "", 
160, TimePoint, 1156, 1164, "baseline", "", 
161, Mean, 1203, 1207, "Mean", "", 
169, Year, 1240, 1245, "years", "", 
170, Year, 1282, 1287, "years", "", 
48, InsulinDose, 1290, 1304, "insulin dosage", "", 
49, BaseLineValue, 1309, 1311, "55", "", 
50, BioAndMedicalUnit, 1312, 1323, "units / day", "", 
166, TimePoint, 1330, 1338, "baseline", "", 
45, HbA1c, 1339, 1344, "HbA1c", "", "<http://ctro/data#Endpoint_45552> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
46, BaseLineValue, 1349, 1354, "8 . 4", "", 
47, Percentage, 1355, 1356, "%", "", "<http://ctro/data#Endpoint_45552> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
79573, Lixisenatide, 1364, 1376, "lixisenatide", "", 
53, Placebo, 1383, 1390, "placebo", "", 
54, HbA1c, 1413, 1418, "HbA1c", "", 
61, TimePoint, 1424, 1432, "baseline", "", 
55, Reduction, 1439, 1444, "0 . 4", "", "<http://ctro/data#Outcome_45557> <http://ctro/data#hasChangeValue> \"0 . 4\"."
56, Percentage, 1445, 1446, "%", "", 
57, ConfIntervalChangeValue, 1449, 1475, "95 % CI - 0 . 6 to - 0 . 2", "", "<http://ctro/data#Outcome_45557> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI - 0 . 6 to - 0 . 2\"."
58, PValueChangeValue, 1478, 1490, "P = 0 . 0002", "", "<http://ctro/data#Outcome_45557> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 0002\"."
183, Mean, 1499, 1503, "mean", "", "<http://ctro/data#Mean_45554> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_45552> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_45554>."
59, HbA1c, 1504, 1509, "HbA1c", "", 
60, TimePoint, 1510, 1522, "at end point", "", "<http://ctro/data#Outcome_45557> <http://ctro/data#hasTimePoint> \"at end point\"."
62, ResultMeasuredValue, 1527, 1532, "7 . 8", "", "<http://ctro/data#Outcome_45557> <http://ctro/data#hasResultMeasuredValue> \"7 . 8\"."
63, Percentage, 1533, 1534, "%", "", 
64, HbA1c_target, 1537, 1570, "HbA1c < 7 . 0 % ( 53 mmol / mol )", "", "<http://ctro/data#Endpoint_45584> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
187, Percentage, 1551, 1552, "%", "", 
79776, Millimoles_per_mole, 1558, 1568, "mmol / mol", "", 
79574, Lixisenatide, 1592, 1604, "lixisenatide", "", 
67, PercentageAffected, 1607, 1609, "28", "", "<http://ctro/data#Outcome_45589> <http://ctro/data#hasPercentageAffected> \"28\"."
66, Placebo, 1619, 1626, "placebo", "", 
68, PercentageAffected, 1629, 1631, "12", "", "<http://ctro/data#Outcome_45616> <http://ctro/data#hasPercentageAffected> \"12\"."
69, PvalueDiff, 1636, 1648, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_45643> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
79575, Lixisenatide, 1666, 1678, "Lixisenatide", "", 
198, PostprandialPlasmaGlucose, 1687, 1739, "plasma glucose levels after a standardized breakfast", "", "<http://ctro/data#Endpoint_45652> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialPlasmaGlucose>."
73, Placebo, 1742, 1749, "placebo", "", 
83, Reduction, 1776, 1781, "3 . 8", "", "<http://ctro/data#Outcome_45657> <http://ctro/data#hasChangeValue> \"3 . 8\"."
74, Millimoles_per_litre, 1782, 1790, "mmol / L", "", "<http://ctro/data#Endpoint_45652> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
75, PValueChangeValue, 1793, 1805, "P < 0 . 0001", "", "<http://ctro/data#Outcome_45657> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 0001\"."
77, BodyWeight, 1903, 1914, "body weight", "", "<http://ctro/data#Endpoint_45684> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
78, Placebo, 1917, 1924, "placebo", "", 
82, Reduction, 1939, 1944, "1 . 3", "", "<http://ctro/data#Outcome_45694> <http://ctro/data#hasChangeValue> \"1 . 3\"."
79, Kg, 1945, 1947, "kg", "", "<http://ctro/data#Endpoint_45684> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
80, PValueChangeValue, 1950, 1962, "P < 0 . 0001", "", "<http://ctro/data#Outcome_45694> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 0001\"."
81, InsulinDose, 1969, 1983, "insulin dosage", "", "<http://ctro/data#InsulinDose_45690> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#InsulinDose>. <http://ctro/data#Endpoint_45689> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#InsulinDose_45690>."
84, Reduction, 1988, 1993, "3 . 7", "", "<http://ctro/data#Outcome_45721> <http://ctro/data#hasChangeValue> \"3 . 7\"."
85, BioAndMedicalUnit, 1994, 2005, "units / day", "", "<http://ctro/data#BioAndMedicalUnit_45692> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_45689> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_45692>."
86, PValueChangeValue, 2008, 2019, "P = 0 . 012", "", "<http://ctro/data#Outcome_45721> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 012\"."
79578, Lixisenatide, 2040, 2052, "lixisenatide", "", 
91, ObservedResult, 2055, 2124, "Main adverse events ( AEs ) with lixisenatide were gastrointestinal .", "", "<http://ctro/data#Outcome_45754> <http://ctro/data#hasObservedResult> \"Main adverse events ( AEs ) with lixisenatide were gastrointestinal .\"."
88, EndPointDescription, 2060, 2074, "adverse events", "", "<http://ctro/data#EndPointDescription_45750> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_45749> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_45750>."
89, EndPointDescription, 2077, 2080, "AEs", "", 
79576, Lixisenatide, 2088, 2100, "lixisenatide", "", 
92, SymptomaticHypoglycemia, 2125, 2149, "Symptomatic hypoglycemia", "", "<http://ctro/data#Endpoint_45781> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
93, PercentageAffected, 2154, 2156, "28", "", "<http://ctro/data#Outcome_45786> <http://ctro/data#hasPercentageAffected> \"28\"."
79584, Lixisenatide, 2163, 2175, "lixisenatide", "", 
94, PercentageAffected, 2180, 2182, "22", "", "<http://ctro/data#Outcome_45813> <http://ctro/data#hasPercentageAffected> \"22\"."
96, Placebo, 2189, 2196, "placebo", "", 
98, NumberAffected, 2199, 2200, "4", "", "<http://ctro/data#Outcome_45845> <http://ctro/data#hasNumberAffected> \"4\"."
100, NumberPatientsArm, 2204, 2207, "328", "", "<http://ctro/data#Arm_45460> <http://ctro/data#hasNumberPatientsArm> \"328\"."
97, PercentageAffected, 2219, 2224, "1 . 2", "", "<http://ctro/data#Outcome_45845> <http://ctro/data#hasPercentageAffected> \"1 . 2\"."
103, SevereHypoglycemia, 2233, 2252, "severe hypoglycemia", "", "<http://ctro/data#Endpoint_45840> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SevereHypoglycemia>."
79580, Lixisenatide, 2258, 2270, "lixisenatide", "", 
99, NumberAffected, 2276, 2277, "0", "", 
101, NumberPatientsArm, 2281, 2284, "167", "", "<http://ctro/data#Arm_45469> <http://ctro/data#hasNumberPatientsArm> \"167\"."
102, Placebo, 2290, 2297, "placebo", "", 
113, ConclusionComment, 2314, 2561, "By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .", "", "<http://ctro/data#ClinicalTrial_45436> <http://ctro/data#hasConclusionComment> \"By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin , lixisenatide may provide an alternative to rapid - acting insulin or other treatment options .\"."
105, HbA1c, 2327, 2332, "HbA1c", "", 
106, Hypoglycemia, 2337, 2363, "postprandial hyperglycemia", "", 
231, WeightGain, 2372, 2383, "weight gain", "", 
108, Type2Diabetes, 2387, 2402, "type 2 diabetes", "", 
233, Insulin, 2457, 2464, "insulin", "", 
79582, Lixisenatide, 2467, 2479, "lixisenatide", "", 
112, Insulin, 2525, 2532, "insulin", "", 
114, PMID, 2618, 2626, "23628617", "", "<http://ctro/data#Publication_45429> <http://ctro/data#hasPMID> \"23628617\"."
